LYEL
Lyell Immunopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Revenue Plunges
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About LYEL
Lyell Immunopharma, Inc.
A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors
201 Haskins Way, South San Francisco, California 94080
--
Lyell Immunopharma, Inc., was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company that is expected to enter pivotal trials in 2025 and advance a proprietary next-generation pipeline of autologous chimeric antigen receptor T cell product candidates for patients with hematological malignancies and solid tumors. The company is pioneering new methods aimed at generating T cells that drive durable clinical responses. The patient's living cells are the starting point for the company's investigational CAR T cell therapy, which the company enhances with innovative CAR structures, technologies and manufacturing protocols.
Company Financials
EPS
LYEL has released its 2024 Q4 earnings. EPS was reported at -0.71, versus the expected -0.13, missing expectations. The chart below visualizes how LYEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LYEL has released its 2024 Q4 earnings report, with revenue of 11.00K, reflecting a YoY change of -15.38%, and net profit of -191.94M, showing a YoY change of -262.62%. The Sankey diagram below clearly presents LYEL’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
